Literature DB >> 25444816

Persistent BCG bacilli perpetuate CD4 T effector memory and optimal protection against tuberculosis.

Daryan A Kaveh1, M C Garcia-Pelayo1, Philip J Hogarth2.   

Abstract

Tuberculosis (TB) remains one of the most important infectious diseases of man and animals, and the only available vaccine (BCG) requires urgent replacement or improvement. To facilitate this, the protective mechanisms induced by BCG require further understanding. As a live attenuated vaccine, persistence of BCG bacilli in the host may be a crucial mechanism. We have investigated the long term persistence of BCG following vaccination and the influence on the induced immune response and protection, using an established murine model. We sought to establish whether previously identified BCG-specific CD4 TEM cells represent genuine long-lived memory cells of a relatively high frequency, or are a consequence of continual priming by chronically persistent BCG vaccine bacilli. By clearing persistent bacilli, we have compared immune responses (spleen and lung CD4: cytokine producing T effector/TEM; TCR-specific) and BCG-induced protection, in the presence and absence of these persisting vaccine bacilli. Viable BCG bacilli persisted for at least 16 months post-vaccination, associated with specific CD4 T effector/TEM and tetramer-specific responses. Clearing these bacilli abrogated all BCG-specific CD4 T cells whilst only reducing protection by 1log10. BCG may induce two additive mechanisms of immunity: (i) dependant on the presence of viable bacilli and TEM; and (ii) independent of these factors. These data have crucial implications on the rational generation of replacement TB vaccines, and the interpretation of BCG induced immunity in animal models. Crown
Copyright © 2014. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25444816     DOI: 10.1016/j.vaccine.2014.10.041

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

1.  Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques.

Authors:  Michel P M Vierboom; Agnes L Chenine; Patricia A Darrah; Richard A W Vervenne; Charelle Boot; Sam O Hofman; Claudia C Sombroek; Karin Dijkman; Mohamed A Khayum; Marieke A Stammes; Krista G Haanstra; Chantal Hoffmann; Doris Schmitt; Nathalie Silvestre; Alexander G White; H Jacob Borish; Robert A Seder; Nadia Ouaked; Stephane Leung-Theung-Long; Geneviève Inchauspé; Ravi Anantha; Mary Limbach; Thomas G Evans; Danilo Casimiro; Maria Lempicki; Dominick J Laddy; Aurelio Bonavia; Frank A W Verreck
Journal:  NPJ Vaccines       Date:  2020-05-14       Impact factor: 7.344

2.  Immunomodulatory Effects of Adjuvants CPG, MPLA, and BCG on the Derp2-Induced Acute Asthma at Early Life in an Animal Model of BALB/c Mice.

Authors:  V Mohammadi-Shahrokhi; A Rezaei; A Andalib; A Rahnama; A Jafarzadeh; N Eskandari
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

3.  Vaccine-mediated immunity to experimental Mycobacterium tuberculosis is not impaired in the absence of Toll-like receptor 9.

Authors:  Archana Gopalakrishnan; Jillian Dietzold; Padmini Salgame
Journal:  Cell Immunol       Date:  2015-12-30       Impact factor: 4.868

Review 4.  Adaptation and memory in immune responses.

Authors:  Gioacchino Natoli; Renato Ostuni
Journal:  Nat Immunol       Date:  2019-06-18       Impact factor: 25.606

5.  Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosis.

Authors:  Subhadra Nandakumar; Sunil Kannanganat; Karen M Dobos; Megan Lucas; John S Spencer; Rama Rao Amara; Bonnie B Plikaytis; James E Posey; Suraj B Sable
Journal:  Sci Rep       Date:  2016-05-13       Impact factor: 4.379

6.  Efficacy Testing of H56 cDNA Tattoo Immunization against Tuberculosis in a Mouse Model.

Authors:  Anouk C M Platteel; Natalie E Nieuwenhuizen; Teresa Domaszewska; Stefanie Schürer; Ulrike Zedler; Volker Brinkmann; Alice J A M Sijts; Stefan H E Kaufmann
Journal:  Front Immunol       Date:  2017-12-11       Impact factor: 7.561

Review 7.  The Cross-Species Mycobacterial Growth Inhibition Assay (MGIA) Project, 2010-2014.

Authors:  Michael J Brennan; Rachel Tanner; Sheldon Morris; Thomas J Scriba; Jacqueline M Achkar; Andrea Zelmer; David A Hokey; Angelo Izzo; Sally Sharpe; Ann Williams; Adam Penn-Nicholson; Mzwandile Erasmus; Elena Stylianou; Daniel F Hoft; Helen McShane; Helen A Fletcher
Journal:  Clin Vaccine Immunol       Date:  2017-09-05

Review 8.  IFN-γ Priming Effects on the Maintenance of Effector Memory CD4(+) T Cells and on Phagocyte Function: Evidences from Infectious Diseases.

Authors:  Henrique Borges da Silva; Raíssa Fonseca; José M Alvarez; Maria Regina D'Império Lima
Journal:  J Immunol Res       Date:  2015-10-05       Impact factor: 4.818

9.  Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study.

Authors:  Irene Andia Biraro; Moses Egesa; Simon Kimuda; Steven G Smith; Frederic Toulza; Jonathan Levin; Moses Joloba; Achilles Katamba; Stephen Cose; Hazel M Dockrell; Alison M Elliott
Journal:  BMC Infect Dis       Date:  2015-10-22       Impact factor: 3.090

Review 10.  Next-Generation Vaccines Based on Bacille Calmette-Guérin.

Authors:  Natalie E Nieuwenhuizen; Stefan H E Kaufmann
Journal:  Front Immunol       Date:  2018-02-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.